Vanguard Group Inc Hookipa Pharma Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,118,416 shares of HOOK stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,118,416

Previous 2,114,802 0.17%

Holding current value

$1.67 Million

Previous $1.71 Million 12.15%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.61 - $0.83 $2,204 - $2,999	3,614 Added 0.17%	2,118,416 $1.5 Million
Q4 2023 Feb 14, 2024	BUY	$0.42 - $0.86 $124,870 - $255,686	297,310 Added 16.36%	2,114,802 $1.71 Million
Q3 2023 Nov 14, 2023	SELL	$0.58 - $0.91 $2,368 - $3,715	-4,083 Reduced 0.22%	1,817,492 $1.13 Million
Q2 2023 Aug 14, 2023	BUY	$0.71 - $1.97 $49,344 - $136,913	69,499 Added 3.97%	1,821,575 $1.6 Million
Q4 2022 Feb 10, 2023	SELL	$0.73 - $1.31 $8,427 - $15,123	-11,545 Reduced 0.65%	1,752,076 $1.42 Million

Q3 2022 Nov 14, 2022	BUY	$1.27 - $1.87 $142,100 - $209,234	111,890 Added 6.77%	1,763,621 $2.36 Million
Q2 2022 Aug 12, 2022	BUY	$1.33 - $2.31 $708,703 - $1.23 Million	532,860 Added 47.62%	1,651,731 $2.69 Million
Q1 2022 May 13, 2022	BUY	$1.26 - $2.52 $259,949 - $519,898	206,309 Added 22.61%	1,118,871 $2.55 Million
Q4 2021 Feb 14, 2022	BUY	$2.33 - $5.94 $2,010 - $5,126	863 Added 0.09%	912,562 $2.13 Million
Q3 2021 Nov 12, 2021	BUY	$5.89 - $9.35 $62,139 - $98,642	10,550 Added 1.17%	911,699 $5.37 Million
Q2 2021 Aug 13, 2021	BUY	$9.16 - $19.51 $8.25 Million - $17.6 Million	901,149 New	901,149 $8.26 Million

Others Institutions Holding HOOK

# of Institutions

Shares Held

32.5M

Call Options Held

105K

Put Options Held

43.6K

View Full List

About HOOKIPA Pharma Inc.

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $40.8M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

More about HOOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Hookipa Pharma Inc. Transaction History